These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 25034616)

  • 1. Experiences of patients undergoing anti-VEGF treatment for neovascular age-related macular degeneration: a systematic review.
    Boyle J; Vukicevic M; Koklanis K; Itsiopoulos C
    Psychol Health Med; 2015; 20(3):296-310. PubMed ID: 25034616
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Experiences of patients undergoing repeated intravitreal anti-vascular endothelial growth factor injections for neovascular age-related macular degeneration.
    Boyle J; Vukicevic M; Koklanis K; Itsiopoulos C; Rees G
    Psychol Health Med; 2018 Feb; 23(2):127-140. PubMed ID: 28064517
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Aflibercept for the treatment of neovascular age-related macular degeneration.
    Verner-Cole EA; Davis SJ; Lauer AK
    Drugs Today (Barc); 2012 May; 48(5):317-29. PubMed ID: 22645720
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Emerging therapies for neovascular age-related macular degeneration: drugs in the pipeline.
    Kaiser PK
    Ophthalmology; 2013 May; 120(5 Suppl):S11-5. PubMed ID: 23642781
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Profile of conbercept in the treatment of neovascular age-related macular degeneration.
    Lu X; Sun X
    Drug Des Devel Ther; 2015; 9():2311-20. PubMed ID: 25960634
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neovascular age-related macular degeneration: intraocular cytokines and growth factors and the influence of therapy with ranibizumab.
    Funk M; Karl D; Georgopoulos M; Benesch T; Sacu S; Polak K; Zlabinger GJ; Schmidt-Erfurth U
    Ophthalmology; 2009 Dec; 116(12):2393-9. PubMed ID: 19815292
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Age-related macular degeneration: using morphological predictors to modify current treatment protocols.
    Ashraf M; Souka A; Adelman RA
    Acta Ophthalmol; 2018 Mar; 96(2):120-133. PubMed ID: 29130626
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti vascular endothelial growth factor sequential therapy for neovascular age-related macular degeneration: is this the new deal?
    Neri P; Mariotti C; Arapi I; Bambini E; Giovannini A
    Curr Med Res Opin; 2012 Mar; 28(3):395-400. PubMed ID: 22283373
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Optical Coherence Tomography Monitoring Strategies for A-VEGF-Treated Age-Related Macular Degeneration: An Evidence-Based Analysis.
    Pron G
    Ont Health Technol Assess Ser; 2014; 14(10):1-64. PubMed ID: 26316918
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hot Topics in Pharmacotherapy for Neovascular Age-Related Macular Degeneration.
    Falavarjani KG; Sadda SR
    Curr Pharm Des; 2017; 23(4):535-541. PubMed ID: 27981904
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Current anti-vascular endothelial growth factor dosing regimens: benefits and burden.
    Haller JA
    Ophthalmology; 2013 May; 120(5 Suppl):S3-7. PubMed ID: 23642784
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment as Required versus Regular Monthly Treatment in the Management of Neovascular Age-Related Macular Degeneration: A Systematic Review and Meta-Analysis.
    Schmucker CM; Rücker G; Sommer H; Virgili G; Loke YK; Oeller P; Agostini H; Ehlken C
    PLoS One; 2015; 10(9):e0137866. PubMed ID: 26368921
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anti-VEGF treatment patterns for neovascular age-related macular degeneration among medicare beneficiaries.
    Lad EM; Hammill BG; Qualls LG; Wang F; Cousins SW; Curtis LH
    Am J Ophthalmol; 2014 Sep; 158(3):537-43.e2. PubMed ID: 24857687
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risk of geographic atrophy in age-related macular degeneration patients treated with intravitreal anti-VEGF agents.
    Gemenetzi M; Lotery AJ; Patel PJ
    Eye (Lond); 2017 Jan; 31(1):1-9. PubMed ID: 27716750
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Intravitreal anti-VEGF injections improve the visual prognosis of wet age related macular degeneration].
    Ambresin A; Mantel I
    Rev Med Suisse; 2007 Jan; 3(94):137-41. PubMed ID: 17354539
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A systematic review of the efficacy and safety outcomes of anti-VEGF agents used for treating neovascular age-related macular degeneration: comparison of ranibizumab and bevacizumab.
    Mitchell P
    Curr Med Res Opin; 2011 Jul; 27(7):1465-75. PubMed ID: 21623685
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intravitreal anti-VEGF injections for treating wet age-related macular degeneration: a systematic review and meta-analysis.
    Ba J; Peng RS; Xu D; Li YH; Shi H; Wang Q; Yu J
    Drug Des Devel Ther; 2015; 9():5397-405. PubMed ID: 26451092
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Current therapeutic approaches in neovascular age-related macular degeneration.
    Nguyen DH; Luo J; Zhang K; Zhang M
    Discov Med; 2013 Jun; 15(85):343-8. PubMed ID: 23819948
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevention and treatment of age-related macular degeneration: an update for pharmacists.
    Marshall LL; Roach JM
    Consult Pharm; 2013 Nov; 28(11):723-37. PubMed ID: 24217192
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Retrospective investigation of anti-VEGF treatment reality and effectiveness in patients with neovascular age-related macular degeneration (AMD) in Germany: treatment reality of ranibizumab for neovascular AMD in Germany].
    Ziemssen F; Eter N; Fauser S; Bopp S; Radermacher M; Hasanbasic Z; Holz FG;
    Ophthalmologe; 2015 Mar; 112(3):246-54. PubMed ID: 25668709
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.